{
    "clinical_study": {
        "@rank": "147900", 
        "arm_group": [
            {
                "arm_group_label": "Osmotic dilators + placebo (vit c) + placebo (vit B12)", 
                "arm_group_type": "Other", 
                "description": "Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2."
            }, 
            {
                "arm_group_label": "Osmotic dilators + placebo (vit c) + misoprostol", 
                "arm_group_type": "Active Comparator", 
                "description": "Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2."
            }, 
            {
                "arm_group_label": "Osmotic dilators + mifepristone + placebo (vit B12)", 
                "arm_group_type": "Active Comparator", 
                "description": "Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to compare three different ways of opening a woman's\n      cervix before her second-trimester surgical abortion.\n\n        -  Osmotic dilators: small rods that, when inserted into the cervix, gently expand to open\n           the cervix\n\n        -  Osmotic dilators plus mifepristone, a medicine that is swallowed\n\n        -  Osmotic dilators plus misoprostol, a medicine that is placed between the cheek and gum\n\n      Hypotheses:\n\n        -  adding buccal misoprostol 3 hours preoperatively will significantly improve dilation\n           compared to laminaria alone, making procedures faster, easier and safer.\n\n        -  adding oral mifepristone at the time of laminaria placement will confer a similar\n           benefit.\n\n        -  the efficacy of adjunctive misoprostol and mifepristone will be influenced by\n           gestational age, with women later in gestation having increased efficacy from these\n           agents.\n\n        -  significantly more patients who receive adjunctive misoprostol or mifepristone will\n           have adequate initial dilation, fewer will require manual dilation or additional\n           cervical preparation and there will be fewer complications in these arms, although\n           complication rates will be low and we will only be able to detect relatively large\n           differences.\n\n        -  patients will prefer to have the procedure done as quickly as possible with as little\n           discomfort as possible, that cervical ripening with adjunctive misoprostol will be\n           associated with more cramping than osmotic dilators alone and that mifepristone will be\n           well tolerated and may not cause more cramping or other side effects than osmotic\n           dilators alone."
        }, 
        "brief_title": "Cervical Preparation Before Dilation and Evacuation", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Abortion, Induced", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years and older\n\n          -  Able to give informed consent\n\n          -  Medically eligible for outpatient second trimester pregnancy termination at the\n             clinical site\n\n          -  English-speaking or Spanish-speaking at sites with ability to obtain informed consent\n             in Spanish\n\n        Exclusion Criteria:\n\n          -  Active bleeding (>1 pad/hour) or hemodynamically unstable at enrollment\n\n          -  Signs of chorioamnionitis or clinical infection at enrollment\n\n          -  Signs of spontaneous labor or cervical insufficiency at enrollment\n\n          -  Spontaneous intrauterine fetal demise\n\n          -  Patient incarcerated\n\n          -  Allergy to mifepristone or misoprostol\n\n          -  Chronic steroid use or adrenal insufficiency\n\n          -  Porphyria\n\n          -  Inflammatory bowel disease requiring treatment"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01799928", 
            "nct_id": "NCT01751087", 
            "org_study_id": "9-500-25.1", 
            "secondary_id": "SFPRF6-MS"
        }, 
        "intervention": [
            {
                "arm_group_label": "Osmotic dilators + mifepristone + placebo (vit B12)", 
                "description": "oral mifepristone 200 mg on Day 1.", 
                "intervention_name": "Mifepristone", 
                "intervention_type": "Other", 
                "other_name": "Mifeprex"
            }, 
            {
                "arm_group_label": "Osmotic dilators + placebo (vit c) + misoprostol", 
                "description": "buccal misoprostol 400 mcg on Day 2", 
                "intervention_name": "misoprostol", 
                "intervention_type": "Drug", 
                "other_name": "Cytotec"
            }, 
            {
                "arm_group_label": [
                    "Osmotic dilators + placebo (vit c) + placebo (vit B12)", 
                    "Osmotic dilators + placebo (vit c) + misoprostol", 
                    "Osmotic dilators + mifepristone + placebo (vit B12)"
                ], 
                "description": "osmotic dilators on Day 1", 
                "intervention_name": "Osmotic dilators", 
                "intervention_type": "Device", 
                "other_name": [
                    "laminaria", 
                    "Dilapan-S"
                ]
            }, 
            {
                "arm_group_label": [
                    "Osmotic dilators + placebo (vit c) + placebo (vit B12)", 
                    "Osmotic dilators + placebo (vit c) + misoprostol"
                ], 
                "description": "placebo for mifepristone, on day 1", 
                "intervention_name": "placebo", 
                "intervention_type": "Other", 
                "other_name": "vitamin C 500 mg"
            }, 
            {
                "arm_group_label": [
                    "Osmotic dilators + placebo (vit c) + placebo (vit B12)", 
                    "Osmotic dilators + mifepristone + placebo (vit B12)"
                ], 
                "description": "placebo for misoprostol, on day 2", 
                "intervention_name": "placebo", 
                "intervention_type": "Other", 
                "other_name": "vitamin B12 500 mcg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mifepristone", 
                "Misoprostol", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "abortion, induced", 
        "lastchanged_date": "March 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "San Francisco General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60630"
                    }, 
                    "name": "Family Planning Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Boston Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham and Women's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10012"
                    }, 
                    "name": "Planned Parenthood of New York City"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Lovejoy Surgical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Magee Women's Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Cervical Preparation Before Dilation and Evacuation in the Second Trimester: A Multicenter Randomized Trial Comparing Osmotic Dilators Alone to Dilators Plus Adjunctive Misoprostol or Adjunctive Mifepristone.", 
        "overall_official": {
            "affiliation": "Planned Parenthood League of Massachusetts", 
            "last_name": "Principal Investigator, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Operative time", 
            "safety_issue": "No", 
            "time_frame": "measured with a stopwatch, starting with the first instrument that passes into the uterus and ending when the last instrument is removed from the uterus upon completion of the D&E"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01751087"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "initial cervical dilation", 
                "safety_issue": "No", 
                "time_frame": "measured immediately before start of D&E"
            }, 
            {
                "measure": "ability to complete the D&E on the first attempt", 
                "safety_issue": "No", 
                "time_frame": "assessed after completion of D&E"
            }, 
            {
                "measure": "need for mechanical dilation", 
                "safety_issue": "No", 
                "time_frame": "assessed after completion of D&E"
            }, 
            {
                "measure": "ease of mechanical dilation", 
                "safety_issue": "No", 
                "time_frame": "assessed after completion of D&E"
            }, 
            {
                "description": "bleeding requiring additional intervention, infection, additional surgery, transfer to hospital", 
                "measure": "complications from procedure", 
                "safety_issue": "Yes", 
                "time_frame": "assessed immediately after completion of D&E and at 1 week and 1 month post-procedure"
            }, 
            {
                "measure": "pain with procedure", 
                "safety_issue": "No", 
                "time_frame": "assessed after completion of D&E"
            }, 
            {
                "description": "nausea, vomiting, diarrhea, cramping, fever", 
                "measure": "side effects", 
                "safety_issue": "No", 
                "time_frame": "assessed after dilator insertion, after day 1 medication, after day 2 medication and after D&E procedure"
            }, 
            {
                "measure": "patient acceptability of dilation method", 
                "safety_issue": "No", 
                "time_frame": "assessed after completion of D&E procedure"
            }, 
            {
                "measure": "provider acceptability of dilation method", 
                "safety_issue": "No", 
                "time_frame": "assessed after completion of D&E procedure"
            }
        ], 
        "source": "Planned Parenthood League of Massachusetts", 
        "sponsors": {
            "collaborator": {
                "agency": "Society of Family Planning", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Planned Parenthood League of Massachusetts", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}